Novel drugs approved by the EMA, the FDA and the MHRA in 2025
Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease
Exactly how GLP-1R agonists may be having their neuroprotective effect in the models of Parkinsons is still being determined
Many report eating smaller portions without feeling deprived, and cravings for unhealthy snacks often start to diminish
Let it dry completely, which takes about 10 seconds
This makes it a valuable tool for patients struggling with obesity or related conditions such as type 2 diabetes